Identifying Networks Underlying Compulsivity in Anorexia Nervosa for Targeting With Neuromodulation
NCT06138782
Recruiting
Transcranial Magnetic Stimulation (TMS) is approved by the Food and Drug Administration (FDA) for the treatment of refractory Major Depressive Disorder (MDD) and obsessive-compulsive disorder (OCD). Anorexia nervosa (AN) is characterized by restrictive eating leading to low weight and associated complications. There is an emerging understanding that the symptoms of OCD and AN overlap as AN can be characterized by obsessive thought patterns around food and compulsive restricting and weight loss b... Read More
Gender:
ALL
Ages:
Between 16 years and 75 years
Trial Updated:
06/04/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Anorexia Nervosa
Register for Updates
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941
Recruiting
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/04/2025
Locations: Arizona Arthritis and Rheumatology Research PLLC, Mesa, Arizona +45 locations
Conditions: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Register for Updates
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
NCT06515470
Recruiting
The purpose of this study is to test BTX-9341 alone or in combination with fulvestrant (a currently marketed medication for breast cancer) in participants with advanced and/or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The study includes a dose escalation part (Part A) where small groups of participants will receive increasing doses of BTX-9341 or BTX-9341 + fulvestrant followed by a dose expansion part (Part B) where parti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Biotheryx Investigative Site, Rochester, Minnesota +5 locations
Conditions: Breast Cancer
Register for Updates
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT06682793
Recruiting
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +6 locations
Conditions: Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer, Lung Cancer, CRC, Head and Neck Squamous Cell Cancer, HNSCC, Renal Cell Carcinoma, RCC, Kidney Cancer, Triple Negative Breast Cancer, TNBC, Colorectal Adenocarcinoma
Register for Updates
Controlled Feeding With 24 Hour Recall
NCT06919536
Recruiting
This study examines how accurately adults report their food intake using a common self-report method called the 24-hour dietary recall. While this method is widely used in nutrition research, it often leads to underreporting, especially among individuals with overweight or obesity. However, it is unclear if specific foods are more likely to be misreported. To address this, participants will be served a controlled meal containing both simple foods (e.g., fruit snacks, saltine crackers, cookies,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/04/2025
Locations: Texas Tech University Nutrition and Metabolic Health Initiative, Lubbock, Texas
Conditions: Evaluate Accuracy 24 Dietary Recall
Register for Updates
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
NCT03313778
Recruiting
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: University of Arizona, Tucson, Arizona +33 locations
Conditions: Solid Tumors
Register for Updates
Toward a Computationally-Informed, Personalized Treatment for Hallucinations
NCT04366518
Recruiting
Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manip... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/04/2025
Locations: Connecticut Mental Health Center, New Haven, Connecticut
Conditions: Hallucinations, Auditory, Psychosis
Register for Updates
Neural Bases of Vocal Sensorimotor Impairment in Aphasia
NCT04742894
Recruiting
Aphasia is the most common type of post-stroke communication disorder characterized by deficits in speech comprehension, production and control. While recovery can be promoted with speech therapy, improvement remains modest and typically requires a large number of sessions contributing to rising health care costs. Traditional aphasia therapy focus on enhancing speech motor output; however, recent evidence suggests that the auditory feedback also plays a critical role in fluent speech. Therefore,... Read More
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
06/04/2025
Locations: University of California Irvine, Irvine, California +2 locations
Conditions: Aphasia
Register for Updates
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
NCT05198323
Recruiting
A phase IIb clinical study to evaluate the safety and efficacy of single or multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS) undergoing endovascular thrombectomy (EVT).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/04/2025
Locations: CHI Memorial Hospital, Chattanooga, Tennessee +1 locations
Conditions: Acute Ischemic Stroke
Register for Updates
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
NCT05705401
Recruiting
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/04/2025
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona +408 locations
Conditions: HER2-positive Breast Cancer
Register for Updates
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
NCT05922930
Recruiting
To find the recommended dose of TROP2- CAR-NK given intraperitoneally (directly into the abdominal cavity) to patients with highgrade serous ovarian cancer that has not responded to previous treatment or is resistant to treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma
Register for Updates
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
NCT06140524
Recruiting
The primary purpose of the study is to understand how well the study drug can eliminate abnormal plasma cells and laboratory signs of high-risk monoclonal gammopathy of undetermined significance (HR-MGUS) and non high-risk smoldering multiple myeloma (NHR-SMM). This requires understanding the safety and tolerability of the study drug (how the body reacts to linvoseltamab) as well as the effectiveness of the study drug (how well linvoseltamab eliminates plasma cells). All participants will start... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland +11 locations
Conditions: Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
Register for Updates